XCUR News and Press, Exicure Inc. From 02/24/23

Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced the closing of the previously-announced private placement transaction with CBI USA, Inc. (“CBI ...

Penny Stocks To Buy According To Insiders Whether you’re trading higher-priced or penny stocks, the year-end trends are mixed in 2022. While some may presume tax-loss selling is going to weigh heavier, others are loading up on their current holdings. In this article, we look at a few n...

Penny Stocks To Buy According to Company Insiders In December When you think about the end of the year, tax-loss selling is a more frequently discussed topic than loading up on penny stocks . But this isn’t an average year, and penny stocks are trading in typical conditions. As you...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com We’re starting off the day with a breakdown of the biggest pre-market stock movers for Tuesday morning! Pharmaceutical and healthcare stocks dominate our lists this morning with ...

Exicure ( NASDAQ: XCUR ) said its collaboration agreements with AbbVie ( ABBV ) and Ipsen BioPharm were terminated. Exicure and AbbVie terminated their agreement related to the development programs targeting hair loss disorders. Meanwhile, Ipsen BioPharm, part of Ips...

Exicure press release ( NASDAQ: XCUR ): Q3 GAAP EPS of -$1.04. Revenue of $2M (+-154.3% Y/Y). Cash, cash equivalents and short-term investments, and restricted cash were $16.8 million as of September 30, 2022, as compared to $48.3 million as of December 31, 2021. The C...

Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today reported financial results for the quarter ended September 30, 2022 and provided an update on its busi...

Early-stage biotech Exicure ( NASDAQ: XCUR ) on Monday announced a host of strategic actions, including a workforce reduction of about 66% and a halt to its research and development activities and its pre-clinical studies. The company estimated that it will incur total expense...

Upon satisfaction of certain closing conditions including approval by Exicure stockholders, existing investor CBI USA, Inc. will purchase an aggregate of 3,400,000 shares of common stock for an aggregate purchase price of $5.4 million, which would result in CBI obtaining a controlling...

Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that CEO Matthias Schroff will pr...